Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Long-Term Investments (2025 - 2026)

Beta Bionics' Long-Term Investments history spans 2 years, with the latest figure at $39.9 million for Q1 2026.

  • On a quarterly basis, Long-Term Investments fell 37.71% to $39.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $39.9 million, a 37.71% decrease, with the full-year FY2025 number at $45.4 million, changed N/A from a year prior.
  • Long-Term Investments hit $39.9 million in Q1 2026 for Beta Bionics, down from $45.4 million in the prior quarter.
  • Over the last five years, Long-Term Investments for BBNX hit a ceiling of $64.0 million in Q1 2025 and a floor of $31.1 million in Q2 2025.